Skip to main content
. 2013 Aug 26;2013:498935. doi: 10.1155/2013/498935

Table 2.

Analyses of anthropometric parameters.

Secondary outcomes (Anthropometric parameters) Period Group P* (P inter)
Placebo group (N = 55) TJ001 group (N = 57)
Mean ± S.D. (P intra) Mean ± S.D. (P intra)
Weight, kg Baseline 83.7 ± 14.4 82.2 ± 10.5 0.5458
week 4 83.2 ± 14.8 80.9 ± 10.2 0.3272
week 8 82.7 ± 13.8 80.7 ± 10.3 0.3900
week 12 82.8 ± 15.1 80.3 ± 10.5 0.3080
Δ0–12 −0.88 ± 3.05 0.0371 −1.95 ± 3.35 <0.0001 0.0708
ANOVA visit X group interaction: P = 0.0816
Body mass index (BMI), kg/cm2 Baseline 31.9 ± 3.80 31.8 ± 2.60 0.8598
week 4 31.6 ± 3.90 31.2 ± 2.60 0.5660
week 8 31.4 ± 3.90 31.2 ± 2.80 0.7407
week 12 31.4 ± 4.10 31.0 ± 2.80 0.5420
Δ0–12 −0.45 ± 1.17 0.0061 −0.75 ± 1.27 <0.0001 0.1680
ANOVA visit X group interaction: P = 0.3703
Waist circumference (WC), cm Baseline 100.4 ± 9.50 99.6 ± 7.00 0.6259
week 4 99.7 ± 9.60 97.6 ± 7.40 0.1932
week 8 98.6 ± 9.30 97.3 ± 7.70 0.3938
week 12 97.3 ± 11.70 96.3 ± 7.90 0.6056
Δ0–12 −3.09 ± 8.57 0.010 −3.29 ± 4.54 <0.0001 0.7665
ANOVA visit X group interaction: P = 0.4725
Hip circumference (HC), cm Baseline 110.4 ± 8.80 109.9 ± 6.00 0.7096
week 4 109.8 ± 8.30 108.4 ± 5.70 0.3027
week 8 109.2 ± 8.40 108.1 ± 5.50 0.4026
week 12 108.6 ± 8.30 107.6 ± 5.70 0.4330
Δ0–12 −1.82 ± 3.48 0.0003 −2.35 ± 3.51 <0.0001 0.3183
ANOVA visit X group interaction: P = 0.3456
Waist/hip ratio (WHR) Baseline 0.91 ± 0.05 0.90 ± 0.05 0.6934
week 4 0.91 ± 0.05 0.90 ± 0.05 0.4217
week 8 0.90 ± 0.04 0.90 ± 0.06 0.6775
week 12 0.90 ± 0.05 0.89 ± 0.05 0.4159
Δ0–12 −0.0073 ± 0.04 0.1307 −0.0114 ± 0.03 0.0108 0.4058
ANOVA visit X group interaction: P = 0.7758

P*: A P value for between-group comparison at each visit and visit X group interaction using ANOVA.

(P intra): A P value for within-group comparison between baseline and 5th visit by paired t-test.

(P inter): A P value for between-group comparison after 12-week treatment using ANCOVA (baseline as covariate).

Δ0–12: Changes between baseline and the 5th visit (after 12-week treatment).

P < 0.05 were considered statistically significant.